SILDENAFIL CITRATE SPRAY AND TABLETS: FIRST RESULTS FROM A SINGLE CENTER COMPARATIVE STUDY


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

Objective. Comparison of the effectiveness of liquid and solid forms of sildenafil citrate. Materials and methods. The study included 16 men with symptoms of erectile dysfunction. Patients were divided into 2 groups depending on the presence of endothelial dysfunction. Each patient received 2 forms of sildenafil citrate with an interval of 3-5 days (spray «Jent» and tablet form). After taking the drug an erotic video was shown (in parallel with penile tumescences monitoring). After 30 and 60 minutes the maximum systolic velocity in the cavernous artery of the penis was determined (Doppler ultrasound). Results. Sildenafil citrate in liquid form begins to act on average after 10.37 minutes in patients with endothelial dysfunction and 9.00 minutes after taking the drug in patients without it. The effect of the liquid form of sildenafil citrate in patients with endothelial dysfunction developed 1.7 times faster than from taking the tablet form (which was not typical for patients without endothelial dysfunction). 62.5% of patients noted an improvement in the quality of erectile function over the next 24 hours after taking the liquid form of the drug and 25% after taking the tablet form. Conclusion. Sildenafil citrate in the form of a spray demonstrates a faster onset of effect in patients with endothelial dysfunction, as well as the presence of a residual effect, which is expressed in an improvement in the quality of erectile function within 24 hours after taking the drug. Sildenafil citrate in the form of a spray can be successfully used in clinical practice for the effective treatment of ED symptoms.

Full Text

Restricted Access

About the authors

A. A Kamalov

Lomonosov Moscow State University

Email: armais.kamalov@rambler.ru
Professor, Dr.Sc. (Med), Academician RAS, Director, Medical Research and Education Center; Head of the Department of Urology and Andrology, Faculty of Fundamental Medicine Moscow, Russia

D. A Ohobotov

Lomonosov Moscow State University

Email: 14072003@rambler.ru
Ph.D. (Med.), Urologist, Medical Research and Education Center, Senior Lecturer, Department of Andrology and Urology, Faculty of Fundamental Medicine Moscow, Russia

A. V Kadrev

Lomonosov Moscow State University

Email: akadrev@yandex.ru
MD, Ph.D., Head of Ultrasound Diagnostics Department; Researcher, Department of Urology and Andrology, Medical Research and Educational Center, Lomonosov Moscow State University; Assistant Professor, Diagnostic Ultrasound Division, Russian Medical Academy of Continuous Professional Education Moscow, Russia

R. M Gorbunov

Lomonosov Moscow State University

Medical Research and Education Center Moscow, Russia

A. P Mikhalchenko

Lomonosov Moscow State University

Medical Research and Education Center Moscow, Russia

A. A Strigunov

Lomonosov Moscow State University

Email: an-strigunov@yandex.ru
PhD student at the Department of Urology and Andrology of the Faculty of Fundamental Medicine Moscow, Russia

O. Yu Nesterova

Lomonosov Moscow State University

Email: oy.nesterova@gmail.com
resident physician at the Department of Urology and Andrology of the Faculty of Fundamental Medicine Moscow, Russia

D. A Tsigura

Lomonosov Moscow State University

Email: darya.cigura@gmail.com
resident physician at the Department of Urology and Andrology of the Faculty of Fundamental Medicine Moscow, Russia

References

  1. NIH Consensus Conference. Impotence. NIH Consensus Development Panel on Impotence. JAMA. United States. 1993;270(1):83-90.
  2. Nehra A., Kulaksizoglu H. Global perspectives and controversies in the epidemiology of male erectile dysfunction. Current opinion in urology. United States. 2002;12(6):493-496.
  3. Stephenson K.R., Truong L., Shimazu L. Why Is Impaired Sexual Function Distressing to Men? Consequences of Impaired Male Sexual Function and Their Associations With Sexual Well-Being. The journal of sexual medicine.Netherlands. 2018;15(9):1336-1349.
  4. EAU Guidelines on Sexual and Reproductive Health. European A. 2020. 232 p.
  5. Эректильная дисфункция. Клинические рекомендации РФ 2021.
  6. Mulhall J.P., Chopra I., Patel D., et al. Phosphodiesterase Type-5 Inhibitor Prescription Patterns in the United States Among Men With Erectile Dysfunction: An Update. The journal of sexual medicine. 2020;17(5):941-948.
  7. Attia A.A.-A., Abdel-Hameed A.K.S., Amer M.A.E.M., et al. Study of the prevalence and patterns of phosphodiesterase type 5 inhibitor use among sexually active Egyptian males: A National Cross-sectional Survey. Andrologia. Germany. 2019;51(9):e13364.
  8. Lindgren S., Janzon L. Prevalence of swallowing complaints and clinical findings among 50-79-year-old men and women in an urban population. Dysphagia. United States. 1991;6(4):187-192.
  9. European Medicines Agency. Guideline on the investigation of bioequivalence. CHMP 2010. Available at: http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2010/01/WC500070039.pdf. Accessed February 22, 2013.
  10. Bataeva Y., Kirichenko V., Kulbashevsky V., et al. The D. Celermajer method and its possibilities in endothelial function assessing. Klinical Informatics and Telemedicine. 2017;12:64-69.
  11. Wang T., Zhuan L., Liu Z., et al. Audiovisual Sexual Stimulation and RigiScan Test for the Diagnosis of Erectile Dysfunction. Chinese medical journal. 2018;131(12):1465-1471.
  12. Badr-Eldin S.M., Ahmed O.A. Optimized nano-transfersomal films for enhanced sildenafil citrate transdermal delivery: ex vivo and in vivo evaluation. Drug design, development and therapy. 2016;10:1323-1333.
  13. Elnaggar Y.S.R., El-Massik M.A., Abdallah O.Y. Fabrication, appraisal, and transdermal permeation of sildenafil citrate-loaded nanostructured lipid carriers versus solid lipid nanoparticles.International journal of nanomedicine. 2011;6:3195-3205.
  14. Lu H.-T., Chen R.-N., Sheu M.-T., et al. Rapid-onset sildenafil nasal spray carried by microemulsion systems: in vitro evaluation and in vivo pharmacokinetic studies in rabbits. Xenobiotica; the fate of foreign compounds in biological systems. England. 2011;41(7):567-577.
  15. Cocci A., Capece M., Cito G., et al. Effectiveness and Safety of Oro-Dispersible Sildenafil in a New Film Formulation for the Treatment of Erectile Dysfunction: Comparison Between Sildenafil 100-mg Film-Coated Tablet and 75-mg Oro-Dispersible Film. The journal of sexual medicine.Netherlands. 2017;14(12):1606-1611.
  16. Shahin H.I., Vinjamuri B.P., Mahmoud A.A., et al. Design and evaluation of novel inhalable sildenafil citrate spray-dried microparticles for pulmonary arterial hypertension. Journal of controlled release : official journal of the Controlled Release Society.Netherlands. 2019;302:126-139.
  17. Beck-Broichsitter M., Bohr A., Aragao-Santiago L., et al. Formulation and process considerations for the design of sildenafil-loaded polymeric microparticles by vibrational spray-drying. Pharmaceutical development and technology. England. 2017;22(6)691-698.
  18. Sawatdee S., Hiranphan P., Laphanayos K., et al. Evaluation of sildenafil pressurized metered dose inhalers as a vasodilator in umbilical blood vessels of chicken egg embryos. European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.Netherlands, 2014;86(1):90-97.
  19. Krivoborodov G.G., Zakharov K.A., Vasilyuk V.B., et al. Pharmacokinetic features of sildenafil spray in healthy men depending on food intake. Urologiia. 2020;5:41-47.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies